

Statin Copays Adversely Affect Outcomes

BY BRUCE JANCIN
Denver Bureau

ATLANTA — Higher prescription statin copayments have unintended negative consequences, Teresa B. Gibson, Ph.D., said at the annual meeting of the American College of Cardiology.

Her study of the health records of more than 93,000 statin users in employer-sponsored health plans demonstrated that higher copays were associated with significantly lower medication adherence, which in turn was linked to more emergency department visits and cardiovascular hospitalizations.

Health plan managers and policy makers use copays as a means of controlling prescription drug costs. It's a strategy designed to reduce consumption of prescription drugs and steer patients to preferred, less expensive medications. The use of copays is likely to continue to

Only 58% of the 93,296 patients had a filled statin prescription on at least 80% of days. Higher copays were associated with a 37% reduction in adherence.

rise. But in patients with chronic medical conditions—such as known cardiovascular disease, or hyperlipidemia predisposing to heart disease—it's a strategy with troublesome side effects, according to Dr. Gibson

of Thomson Medstat, a health care research services company in Ann Arbor, Mich.

"In this large cohort of continuing users of statins, we saw increasing drug copayments are a financial barrier to statin adherence. Reduced cost-sharing might be an effective intervention for these patients," she observed.

The average statin copay during the study period of 2000-2003 was \$12 per month. Overall adherence to statin therapy during the first 18 months was 58%, meaning only 58% of the 93,296 patients had a filled statin prescription on at least 80% of days during follow-up. Higher copays were associated with a 37% reduction in adherence.

Total expenditures measured during the second 18 months of the study period did not differ significantly between statin-adherent and nonadherent patients. Adherent patients had lower medical expenditures, but this was counterbalanced by higher prescription drug expenditures and more physician office visits than for nonadherent patients.

On the other hand, nonadherent patients had more adverse outcomes during the second 18 months as evidenced by significantly more emergency department visits, total hospitalizations, and cardiovascular hospitalizations. Dr. Gibson's study was funded by Pfizer. ■

Vytorin Lowers C-Reactive Protein

BY BRUCE JANCIN
Denver Bureau

ATLANTA — The ezetimibe/simvastatin combination pill Vytorin has a markedly greater anti-inflammatory effect, as reflected in C-reactive protein-lowering, than either agent alone, Dr. Christie M. Ballantyne said at the annual meeting of the American College of Cardiology.


It's already established that Vytorin pro-

duces greater low density lipoprotein (LDL) reductions than does statin monotherapy.

In an effort to learn more about the combination agent's effect on C-reactive protein (CRP)—an emerging risk factor for cardiovascular disease—Dr. Ballantyne and coinvestigators conducted a post hoc pooled analysis of three multicenter, randomized, double-blind, placebo-controlled clinical tri-

The pooled analysis included 3,083 patients with baseline LDL of 145-250 mg/dL who were randomized to 12 weeks of placebo, ezetimibe at 10 mg/day, various doses of Vytorin comprised of ezetimibe 10 mg plus simvastatin 10-80 mg, or simvastatin monotherapy at 10-80 mg/day.

Ezetimibe alone wasn't significantly more effective than placebo at lowering CRP levels. In combination with the various doses of simvastatin, however, it re-



duced CRP by a mean of 31%, compared with 14.3% in the pooled simvastatin monotherapy group, reported Dr. Ballantyne, professor of medicine at Baylor College of Medicine, and director of the Center for Cardiovascular Disease Prevention at Methodist DeBakey Heart Center, Houston.

Simvastatin monotherapy lowered LDL by a mean of 38%, while Vytorin dropped it by 52.5%, he added.

The CRP cutpoint associated with reduced cardiovascular event rates in previous studies has been 2 mg/dL. In the pooled analysis, 47.7% of Vytorin-treated patients achieved both an LDL of less

than 100 mg/dL and a CRP below 2 mg/dL, as did a collective 22.2% of patients on simvastatin monotherapy. The more stringent target of an LDL below 70 mg/dL plus a CRP of less than 2 mg/dL was met by 21.6% of the Vytorin group and 3.2% of patients on simvastatin alone.

That said, Dr. Ballantyne was quick to add that the clinical significance of re-



ducing CRP in patients at increased cardiovascular risk has yet to be established and is the subject of ongoing randomized prospective investigations.

The clinical significance of reducing CRP has yet to be established.

DR. BALLANTYNE

robustly lowering CRP, an especially striking effect given ezetimibe's trivial impact as monotherapy.

Audience members inquired as to the mechanism underlying the apparent synergy between ezetimibe and simvastatin in


“That’s a good question. I wish I had the answer,” Dr. Ballantyne replied. Hypotheses abound.

One such hypothesis is that there is an as-yet unidentified key interaction between the inhibition of cholesterol absorption by ezetimibe and the statin’s 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition.

It’s noteworthy that no enhancement of CRP-lowering was seen in a study in which ezetimibe was combined with fenofibrate rather than a statin, he added.

Dr. Ballantyne is a consultant to Merck/Schering-Plough, which markets Vytorin. ■

DETROL LA is the #1 prescribed brand for OAB*— with BIG REDUCTIONS in OAB symptoms^{1,2}



Van Kerrebroeck et al. *Urology*. 2001;57:414-421.¹
A 12-week, placebo-controlled OAB study. See full study description on next page.

Landis et al. *J Urol*. 2004;171:752-756.²
A post hoc subgroup analysis of Van Kerrebroeck et al. See full study description on next page.

DETROL LA is indicated for the treatment of overactive bladder with symptoms of urge incontinence, urgency, and frequency. DETROL LA is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma and in patients who have demonstrated hypersensitivity to the drug or its ingredients. DETROL LA capsules should be used with caution in patients with clinically significant bladder outflow obstruction, gastrointestinal obstructive disorders, controlled narrow-angle glaucoma, and significantly reduced hepatic or renal function. Dry mouth was the most frequently reported adverse event (DETROL LA 23% vs placebo 8%); others (≥4%) included headache (DETROL LA 6% vs placebo 4%), constipation (DETROL LA 6% vs placebo 4%), and abdominal pain (DETROL LA 4% vs placebo 2%).

* Source: IMS NPA, based on total US prescriptions of antimuscarinics for OAB from October 2001 to December 2005.

† Source: IMS Midas Global Sales Audit, Verispan longitudinal data, based on total prescriptions of DETROL and DETROL LA for OAB from April 1998 to December 2005.

74 million prescriptions[†]

once-daily
Detrol[®] LA
tolterodine tartrate
extended release capsules

Please see important product information on next page.

Improved Control. Less Bother.